Trial · NCT03366207
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
NCT03366207, Phase 4, Completed, Iterum Therapeutics, International Limited; results first posted 2019-08-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI). Trials, record NCT03366207. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03366207
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
- NCT number
- NCT03366207
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 250 participants, actual
- Lead sponsor
- Iterum Therapeutics, International Limited
- Conditions
- UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
- Interventions
- Ciprofloxacin
- First posted
- 2017-12-08
- Last updated
- 2019-09-06
- Results first posted
- 2019-08-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects With Combined Clinical and Microbiologic Response | From start of treatment until assessment of cure, approximately 12 days | Clinical response is defined as complete resolution of uUTI symptoms at entry and no new uUTI symptoms; microbiologic success is defined as eradication of baseline pathogen |
| Secondary | Microbiologic Response | From start of treatment until assessment of cure, approximately 12 days | Microbiologic response is defined as demonstrating \<1000 colony-forming units per mL of the baseline uropathogen at the test of cure visit |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects With Combined Clinical and Microbiologic Response | From start of treatment until assessment of cure, approximately 12 days | Microbiological modified intent to treat population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Microbiologic Response | From start of treatment until assessment of cure, approximately 12 days | Microbiological modified intent to treat | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Combined Clinical and Microbiologic Response | Ciprofloxacin | 70 | Participants | ||
| Microbiologic Response | Ciprofloxacin | 96 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ciprofloxacin | 250 | |
| Overall Study | COMPLETED | Ciprofloxacin | 242 | |
| Overall Study | NOT COMPLETED | Ciprofloxacin | 8 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ciprofloxacin | 0 | 242 |
| Total, other adverse events | Ciprofloxacin | 0 | 242 |
| Total, serious adverse events | Ciprofloxacin | 0 | 242 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03366207
GET https://conductscience.org/api/trials/v1/NCT03366207/registered